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C5-morpholinomethylation of N1-sulfonylcytosines by one-pot 
microwave assisted Mannich reaction 
Josipa Matić,a,b,* Irena Nekola,c Aleksandar Višnjevac,d Renata Kobetić,a Irena Martin-Kleiner,e 
Marijeta Kralj,e,b and Biserka Žinića,b,*  
A fast and efficient route for introduction of methylene bridged-amine (morpholinomethyl) functionality in the C5 position 
of the sulfonylated cytosine nucleobase has been developed. First, novel N1-sulfonylcytosine derivatives 3-6 were prepared 
by the condensation of silylated cytosine with selected sulfonyl chlorides. They were subsequently transformed to 5-
morpholinomethyl-N1-sulfonylcytosine derivatives (8, 12-15) using microwave irradiation. As a result of the cytosine ring 
opening in N1-tosylcytosine, depending on the reaction conditions, peculiar tosyl-urea derivative 9 has been isolated, which 
provided additional insight into reaction pathway. The influence of the C5-substituent on the antiproliferative activity has 
been evaluated by MTT test on U251, MCF-7 and MOLT-4 tumor cell-lines.  
Introduction 
Over the last few decades, in an extensive pursuit for the 
new chemotherapeutics, modified pyrimidine nucleobases and 
nucleosides have emerged as promising antitumor agents.1,2,3 
Numerous patent applications in the recent years prove that 
the interest in these compounds has not decreased.4 On the 
other hand, sulfonyl moiety has been recognized as a potent 
pharmacophore in carbonic anhydrase and metalloprotease 
inhibitors, antifungal, antibacterial, antitumor and other 
biologically active compounds.5,6 Since the sulfonyl-pyrimidines 
present an interesting combination of described 
pharmacophoric components, they have accordingly drawn 
quite attention of our research group. 
Sulfonylated derivatives of cytosine, that we have described 
earlier, have shown strong antiproliferative activity against 
human tumor cell lines in vitro7-12 and in vivo13. These findings 
encouraged us to further investigate modified pyrimidines. It 
has been known that different C5-substituted pyrimidine 
nucleosides often display antitumor activity.14-17 One of the best 
known examples is 5-fluorouracil which is widely used in the 
treatment of cancer.18 Moreover, it has been found that C5-
carbonitrile pyrimidine derivatives modified with heterocyclic 
amines, like piperazine, piperidine and morpholine, could act as 
promoters of apoptosis in cancer cells through cyclin-
dependent kinase 9 inhibition.19 In addition, morpholine moiety 
is present in many drugs, like analgesic dextromoramide, 
antibiotic linezolid or antitumor drug gefitinib.20 
We have decided to prepare a series of N1-sulfonylcytosines 
and an analogous series of N1-sulfonylcytosines with an amine 
(morpholine) substituent in the C5-position. Investigation of 
synthetic efforts for introduction of methylene-bridged 
morpholine moiety in the C5 position of N1-sulfonylcytosine is 
described herein. To the best of our knowledge, C5-
morpholinomethylated derivatives of N1-sulfonylpyrimidine 
have not been reported so far. A secondary goal of the study 
was to evaluate the influence of C5-morpholinomethyl moiety 
on the biological activity of N1-sulfonylcytosines. 
Antiproliferative activity on U251, MCF-7 and MOLT-4 tumor 
cell-lines was examined by MTT test. 
Results and discussion 
Chemistry 
As a part of previous sulfonylcyclourea research, N1-
sulfonylation of cytosine nucleobase was investigated and reaction 
conditions optimized throughout the preparation of N1-
tosylcytosine (2; TsC).21 The reaction was elegantly achieved by 
silylation with N,O-bis(trimethylsilyl)acetamide (BSA) in a dry 
acetonitrile and subsequent addition of appropriate sulfonyl chloride 
(Scheme 1). Novel N1-sulfonyl derivatives 3-6 were prepared in very 
good yield (57–80%). On the other hand, synthesis of 5-
morpholinomethylcytosine 7 was described earlier by Prukała, and it 
was prepared by acid catalyzed Mannich reaction of cytosine with 
paraformaldehyde and morpholine in ethanol.22  
In a quest for new pyrimidine analogs with potential medical 
application, we wanted to prepare cytosine derivatives which 
contain both N1-sulfonyl and C5-morpholinomethyl substituents. 
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First we attempted the sulfonylation of 7 through several known 
methods: 1) activation/silylation of 7 with BSA in CH3CN; 2) activation 
of 7 with 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in N,N-
dimethylformamide (DMF) and 3) activation of 7 with K2CO3 in DMF, 
4) sulfonylation of 7 in pyridine.21 
While method 4) provided traces of desired product 8 (Scheme 
2), other methods resulted solely in isolation of starting compound 7 
as a single product. 
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Scheme 1. Synthesis of N1-sulfonylcytosine derivatives. 
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Scheme 2. N1-sulfonylation of 5-morpholinomethylcytosine 7 in 
pyridine. 
Since sulfonylation of 7 did not yield satisfactory results, we have 
decided to apply reversed synthetic approach. In this attempt, we 
planned to introduce a morpholinomethyl moiety to TsC (2). We 
applied the Prukała method (4h reflux), but a mixture of several 
byproducts was formed. Again, only traces of desired product 8 were 
detected, alongside with a large amount of starting TsC. Upon 
prolongation of the reaction time, complexity of the byproduct 
mixture increased (Supporting information, Figure S14). One of the 
reasons lies in the instability of N-SO2 bond in the given conditions, 
namely several hours of heating in the acidic solution. Detection of 
cytosine (1) in the product mixture supports this assumption. Further 
on, it is well-known that cytidine reacts with formaldehyde in ethanol 
to provide the N-ethoxymethyl cytidine derivative.23 In our case, 
corresponding N-ethoxymethly derivatives of TsC and cytosine were 
isolated from the mixture as well. In addition, as a possible source of 
byproducts, formation of 1,4 adducts in the reaction of cytosine with 
morpholine and formaldehyde has also been described previously.24 
In an attempt to modify this method, we reasoned how to 
provide enough energy for a reaction to occur, but, at the same time, 
shorten the reaction time in order to prevent the formation of 
numerous byproducts. Following this logic, we have turned attention 
to microwave irradiation. Reaction conditions were explored with 
respect to temperature and time (Table 1). Aminomethylation of TsC 
(2) was studied as a model reaction. Two equivalents of morpholine 
and paraformaldehyde and four equivalents of acetic acid in respect 
to starting 2 were used in all entries, as described earlier.22 Unlike 
previously described method, all reagents were added to reaction 
vial at once. The best yield on the compound 8 (65%), was obtained 
when the reaction mixture was heated 30 minutes at 100 C. The 
product precipitated spontaneously from the reaction mixture upon 
cooling, which eliminated the need for a tedious isolation. Product 
was isolated simply by filtration, and purified by recrystallization 
from the methanol. Reasonably good results were obtained from 
reactions at higher temperature (120 C). Although 8 was isolated in 
somewhat reduced yield (32-41%), the purity of the precipitated 
product was much higher and there was no need for recrystallization.  
However, reactions at lower temperatures (80 C) gave the 
unexpected results. As a result of cytosine ring opening, tosylurea 
derivative 9 was isolated in 45% yield, as a main product after 20 
minutes. In addition, yield of 8 dropped significantly (Table 1). The 
amount of 9 decreased with prolongation of the reaction time, to 
disappear almost completely at higher temperatures. At 100 C, 9 
was isolated in only 2% yield after 20 minutes in a microwave reactor, 
while at longer reaction times merely traces were detected. 
Formation of similar acyclic analogues of uracil and cytosine was 
reported as a result of photoreactions in the presence of 
ethylamine.25  
Table 1. Optimization of reaction conditions for the Mannich 
aminomethylation of N1-sulfonylpyrimidines. 
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In a separated experiment, we have proven that 9 undergoes ring 
closure upon heating. When 9 was heated for 1 hour in a microwave 
reactor at 100 C, in pure ethanol, traces of TsC (2) were detected. 
Furthermore, heating of 9 in acidic ethanol solution resulted in 
almost complete conversion into TsC after one hour. It is reasonable 
to assume that higher reaction temperatures promote formation of 
Entry Temp. Time Yield of 8 Yield of 9 
1 80 C 20 min 23% 45% 
2 80 C 30 min 27% 30% 
3 80 C 40 min 48% 22% 
4 80 C 50 min 49% 17% 
5 80 C 60 min 49% 16% 
6 100 C 20 min 33% 2% 
7 100 C 30 min 65% traces 
8 100 C 40 min 56% traces 
9 120 C 20 min 41% 0% 
10 120 C 30 min 34% 0% 
11 120 C 40 min 32% 0% 
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5-morpholinomethyl-N1-tosylcytosine (8), by cyclization of 
tosylurea-derivative 9 into starting TsC. 
It is important to emphasize the significance of order in which the 
reagents were added. When we heated the reaction mixture prior to 
addition of acetic acid, as reported in described method, 5-
morpholinomethylcytosine (7) was isolated as a main product.22 This 
is due to the N-SO2 bond breakage of TsC, which takes place in these 
conditions. In addition, as a result of the transamination reaction, an 
adduct 10 of morpholine and p-toluenesulfonic acid was isolated as 
well (Scheme 3). 
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Scheme 3. Sequential addition of reagents leading to N-SO2 bond 
breakage of TsC (2). 
Once the optimal conditions for Mannich reaction were 
established, we have expanded the reaction scope on the series of 
N1-sulfonyl-aromatic and -polyaromatic cytosine derivatives 12-15 
(Schemes 4 and 5, Table 2). Interestingly, the dominant reaction with 
the compound 3 was substitution of chlorine with morpholine 
(Scheme 4). Compound 11 was isolated in 83% yield. 5-
morpholinomethyl-derivative 12 was isolated when the 11 was 
subsequently subjected to the established Mannich conditions, or 
alternatively, when the compound 3 was treated with double 
amount of reagents (four equivalents of morpholine and 
paraformaldehyde and eight equivalents of acetic acid). 
N
N
NH2
O
SO
O
NO2
Cl
100 °C
30 min
EtOH, MW
N
N
NH2
O
SO
O
NO2
N
O
100 °C
30 min
EtOH, MW
HN
N
NH
O
SO
O
NO2
N
O
83%
100 °C
30 min
EtOH, MW3
N
O
12
3:HCOH:          :AcOH/
1:2:2:4
11
11:HCOH:          :AcOH/
1:2:2:4
3:HCOH:          :AcOH/
1:4:4:8
55%
48%
O
H
N
O
H
N
O
H
N
 
Scheme 4. Synthetic routes for the preparation of 5-
morpholinomethyl derivative 12. 
However, 30 minute-reaction at 100 C did not provide adequate 
results with compounds 4-6, bearing sulfonylbiphenyl or azobenzene 
substituents at N1-position (Scheme 5). Major amount of starting 
compound (77-100%) was isolated after the reaction. Also, 
corresponding sulfonyl-urea derivative was isolated from reaction 
with methyl-biphenyl derivative 4. Nevertheless, 13 and 14 were 
prepared in good yields (52 and 49%) when higher temperature (120 
C) was applied for 30 minutes (Table 2). Compound 15 was isolated 
in somewhat modest yield (30%) after 60 minutes at 120 C. 
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Scheme 5. Synthesis of 5-morpholinomethyl derivatives 12-15. 
Table 2. Reaction conditions for the synthesis of 5-
morpholinomethyl derivatives 8, 12-15. 
N1-comp. N1-C5-
comp. 
Temp.  Time Yield 
2 8 100 C 30 min 65% 
3 12 100 C 30 min 55% 
11 12 100 C 30 min 48% 
4 13 120 C 30 min 52% 
5 14 120 C 30 min 49% 
6 15 120 C 60 min 30% 
Characterization of the products 
NMR spectra 
Structure of 5-morpholinomethyl-N1-tosylcytosine (8) was 
confirmed by 2d NMR spectroscopy. Absence of characteristic C5-
proton signal in 1H NMR spectrum, as well as coupling interaction of 
C6-proton with methylene protons in COSY spectrum confirms that 
the aminomethylation occurred at the C5-position of cytosine base 
(Supporting information, Figure S13). According to the chemical 
shifts of NH-protons, aminomethylated cytosine base of the 
compound 8 occupies keto-imino tautomeric form.26  
Protons of acyclic urea derivative 9 exhibit significant shifts in 
NMR spectra compared to TsC (2) and 8, indicating dramatically 
different structure. Signals of tosyl-protons of 9 are shifted upfield 
for about 0.2 ppm, and morpholine N-CH2 protons are 0.9 ppm 
shifted downfield, compared to 8. The most pronounced shift of 1.2 
ppm displays vinyl CH proton, compared to C5 proton of TsC.  
The acyclic structure of 9 was not unambiguously determined by 
NMR in solution (DMSO-d6) and therefore, additional studies were 
performed in gas-phase (mass spectrometry) and solid phase (single 
crystal diffraction X-ray). 
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Mass Spectra  
H/D exchange experiments were performed to prove open 
cytosine structure of 9, with three fast exchangeable protons, in 
contrast to N1-substituted cytosine molecule, having only two 
exchangeable protons. The collision-induced fragmentation (CID) 
experiments of 9 showed completely different composition of the 
obtained fragments in regards to the open structure. N1-substituted 
cytosine molecular ion increases mass by 2 i.u while molecular ion of 
9 increased by 3 i.u. Additionally, we observed that 9 has three not 
equivalent C-N bonds in the gas phase (Figure 1). Heterolytic bond 
cleavage of 9 molecular ion (m/z for [M+H]+ 353 or [M+D]+ 356) 
occurred at three positions. The variation of the collision energy (CE 
5-20 eV) or the ionization mode (ES+ or ES-) yielded the major 
fragment formed upon the a bond cleavage. (e.g. the most abundant 
signal at m/z 182.1 in ES+). Bond a was the most unstable C-N bond, 
followed by c and finally b (Figures 1 and 2).  
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Figure 1. Marked up three C-N bonds that have similar but not the 
equivalent bonds in the gas phase. Bond a is the most unstable C-N 
bond, followed by c and finally b. 
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Figure 2. Full scan ES+ spectrum for compound 9 dissolved in 
methanol (A) and deutero methanol (B) at about 10-6 mol dm-3. 
Inserted spectrum is PI for molecular ion signals m/z for [M+H]+ 353 
(CH3OH) and m/z 356 for [M+D]+ (CD3OD). 
Molecular and crystal structure 
Molecular structure of 9 reveals no peculiarities, with the 
exception of an unexpected proton migration from N8 to N12 and 
formation of a zwitterionic molecule that was discovered by the X-
ray single crystal diffraction studies. Morpholine unity is in a usual 
chair conformation (Figure 3). 
 
Figure 3. ORTEP drawing of compound 9 with the atom numbering. 
Displacement parameters are scaled to 50 % probability value. 
Crystal packing of 9 is characterized by intensive networks of 
hydrogen bonds in which the co-crystallized water molecules of O5 
and O6 are heavily involved (Table 3, Figures 4 and 5).  
 
Figure 4. Hydrogen bonding pattern in the structure of 9. 
 
Figure 5. The H-bonded molecular tube a motif of the crystal 
packing in the structure of 9. 
The water molecule of O5 acts as a hydrogen bonding bridge 
between two main molecules (mutually related by the symmetry 
operation 1+x, y, z) being H-bonded to the deprotonated N8 of the 
first main molecule by its hydrogen H5A, and to the sulphonyl oxygen 
of the second one by its remaining hydrogen, H5B. The  
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Table 3. Hydrogen bonds in the structure of 9. 
D-H ˑˑˑA D-H (Å) H ˑˑˑA (Å) DˑˑˑA (Å) D-H ˑˑˑA (°) symm op. on A 
O5-H5AˑˑˑN8 0.90 (4) 2.10 (4) 2.992 (2) 174 (3) 1  
O5-H5BˑˑˑO2iii 0.85 (3) 2.02 (3) 2.855 (2) 168 (3) 1+x, y, z 
O6-H6AˑˑˑO1i 0.75 (3) 2.35 (3) 3.047 (3) 155 (3) 1-x, 1-y, 1-z 
O6-H6AˑˑˑN8i 0.75 (3) 2.49 (4) 3.103 (2) 139 (3) 1-x, 1-y, 1-z 
O6-H6BˑˑˑO5 0.78 (3) 2.05 (3) 2.830 (2) 174 (4) 1 
N10-H10ˑˑˑO5i 0.89 (2) 2.19 (2) 3.075 (2) 171 (2) 1-x, 1-y, 1-z 
N12-H12AˑˑˑO6ii 0.87 (3) 2.01 (3) 2.875 (2) 172 (2) 1-x, 2-y, 1-z 
N12-H12BˑˑˑO3 0.89 (3) 2.02 (3) 2.657 (2) 128 (2) 1 (intra)
remaining water molecule (of O6) connects through its hydrogen 
atom H6B to the water molecule of O5, while its second hydrogen, 
H6A acts as a double donor forming two hydrogen bonds, towards 
the sulfonyl oxygen O1i and deprotonated nitrogen N8i, of the 
neighboring main molecule (related by the symmetry operation 1-x, 
1-y, 1-z). Hence, the deprotonated nitrogen N8 acts as a double 
acceptor of the hydrogen bonds, connecting the main molecule to 
both of the co-crystallized water molecules. Finally, the protonated 
imino-nitrogen N12 effectuates a single intra-molecular H-bond in 
this structure, via its hydrogen H12B to the carbonyl oxygen O3. With 
its remaining hydrogen, H12A, N12 forms the hydrogen bond 
towards the co-crystallized water molecule of O6ii. All these 
interactions contribute to a construction of a two dimensional 
molecular tube of the (roughly measured) dimensions 4.58 Å x 6.24 
Å, stretching parallel to the 100 crystallographic plane (Figure 5). 
In vitro screening of antitumor activity 
Antiproliferative activity of 2 (tosyl-derivative) on various tumor 
cell lines was extensively reviewed in previous studies, showing 
moderate activity on MCF-7 cells and no activity towards MOLT-4 
cells.7,11 The activity of new compounds was tested using MTT assay. 
Compounds showed diverse effect on proliferation of U251, MCF-7 
and MOLT-4 tumor cell lines (Table 4). Among N1-sulfonylcytosine 
derivatives, compounds 3 (4-chloro-3-nitrophenyl-derivative), 4 
(methylbiphenyl-derivative) and 5 (methoxybiphenyl-derivative) 
showed low micromolar IC50 activities, especially on MCF-7 and 
MOLT-4 cell lines.  
Introduction of C5-morpholinomethyl group produced very 
heterogeneous effect on the antitumor activity, strongly depending 
on the N1-substituent. Tosyl-derivative 8 and azobenzene-derivative 
15 showed very modest activity. Introduction of C5-
morpholinomethyl moiety completely deteriorated antitumor 
activity in 15, compared to its moderately active N1-sulfonyl 
analogue 6. Introduction of two morpholine units also diminished 
activity in the compound 12, which showed moderate activity, 
compared to very active N1-sulfonyl analogue 3. However, insertion 
of C5-morpholinomethyl moiety had favorable influence on the 
antitumor activity of biphenyl-derivatives. Compounds 13 
(methylbiphenyl-derivative) and 14 (methoxybiphenyl-derivative) 
exhibited even more pronounced antiproliferative activity toward 
U251 cell line than their N1-sulfonyl analogues 4 and 5. At the same, 
13 and 14 preserved remarkable potency toward MCF-7 and MOLT-
4 cell lines. 
Table 4. Antiproliferative activity of the new compounds. 
Compound IC50
a/μM 
U251 MCF-7 MOLT-4 
3 3 ± 2 4 ± 3 2 ± 1 
4 22 ± 1 3 ± 0.2 1 ± 0.1 
5 23 ± 2 3 ± 1 5 ± 2 
6 8 ± 3 30 ± 11 >100 
8  ≥100 ≥100 ≥100 
12  61±1 28±3 18±2 
13 4±0.6 2±0.2 2±0.1 
14  3±0.2 2±0.5 2±0.1 
15  46±38 >100 >100 
aIC50; the concentration that causes 50% growth inhibition 
Experimental 
Materials and apparatus 
Solvents were distilled from appropriate drying agents shortly 
before use. Microwave assisted reaction was conducted in a 
borosilicate glass vials sealed by reusable snap-cap with PTFE coated 
silicone septum. The microwave heating was performed in the Anton 
Paar microwave synthesis reactor Monowave 300. After completed 
irradiation, the reaction tube was cooled with high-pressure air until 
the temperature had fallen below 55 °C. TLC was carried out on 
DCplastikfolien Kieselgel 60 F254 and preparative thin layer (2 mm) 
chromatography was done on Merck 60 F254. NMR spectra were 
recorded on 600 and 300 MHz spectrometers. Mass spectrometry 
was performed on the Agilent 6410 Triple Quad mass spectrometer 
(Agilent Technologies). High resolution mass spectra (HRMS) were 
obtained using a MALDI-TOF/TOF mass spectrometer 4800 Plus 
MALDI TOF/TOF analyzer (Applied Biosystems Inc., Foster City, CA, 
USA). FT-IR spectra of the samples in KBr pellets were recorded at 
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resolution of 4 cm-1 on an ABB Bomem MB102 single-beam 
spectrometer. The electronic absorption spectra of newly prepared 
compounds were measured on a Varian Cary 100 Bio spectrometer. 
Synthesis 
General procedure for the preparation of N1-sulfonylcytosine 
derivatives (3−6) 
A mixture of cytosine 1 (1 mmol) and BSA (3 mmol) was 
heated under reflux in dry acetonitrile (2 mL) for 30 min. The 
solution was cooled to 0 C and sulfonyl chloride (1 mmol) was 
added. After heating under reflux for 60 min a small amount of 
ammonia/methanol was added in the reaction mixture which 
immediately resulted in precipitation of crystals. Solid was 
filtered off and washed with cold methanol. Crude product was 
recrystallized from methanol to give analytically pure sample. 
N1-(4-chloro-3-nitrophenylsulfonyl)cytosine (3): Synthesis 
was performed according to the general procedure with 4-
chloro-3-nitrobenzenesulfonyl chloride to give the product 3 
(453 mg, 77%) as white crystals.  
M.p. = 222–224 °C; Rf = 0.3 (CH2Cl2:CH3OH/9:1); UV (MeOH): 
λmax/nm: 225 and 247; log ε/ dm3 mol–1 cm–1: 4.21 and 4.21; IR 
(KBr) νmax/cm–1: 3381 (m), 3099 (m), 1672 (s), 1659 (s), 1593 (w), 
1572 (w), 1535 (s), 1491 (m), 1387 (m), 1356 (s), 1283 (m), 1256 
(w), 1234 (w), 1188 (s), 1111 (m), 1097 (m), 1058; (w), 1020 (w); 
1H NMR (DMSO-d6) δ/ppm: 8.66 (d, 1H, J = 2.2 Hz, Ar), 8.28 (dd, 
1H, J1 = 8.6 Hz, J2 = 2.3 Hz, Ar), 8.15–7.95 (m, 4H, Ar, H-6, NH2), 
6.00 (d, 1H, J5,6 = 7.9 Hz, H-5); 13C NMR (DMSO-d6) δ/ppm: 166.1 
(Cq), 150.8 (Cq), 147.2 (Cq), 139.2 (CH, C-6), 137.1 (Cq), 133.6 (CH, 
Ar), 132.7 (CH, Ar), 131.4 (Cq), 126.2 (CH, Ar), 98.0 (CH, C-5). (see 
Supporting information Fig. S1) ESI-MS: calcd. for C10H7ClN4O5S: 
330.0; found [M+H]+ at m/z 331.0. 
N1-(4’-methylbiphenyl-4)sulfonylcytosine (4): Synthesis 
was performed according to the general procedure with 4’-
methylbiphenyl-4-sulfonyl chloride to give the product 4 (217 
mg, 72%) as white crystals. 
M.p. = 244–245 °C; Rf = 0.5; UV (MeOH): λmax/nm: 284; log ε/ 
dm3 mol–1 cm–1: 2.58; IR (KBr) νmax/cm–1: 3377 (m), 3107 (m), 
3069 (w), 3030 (w), 1676 (s), 1595 (w), 1524 (s), 1483 (s), 1373 
(m), 1362 (m), 1283 (m), 1232 (w), 1171 (s), 1148 (w), 1115 (w), 
1092 (m), 1024 (w), 1005 (w); 1H NMR (DMSO-d6) δ/ppm: 8.15 
(d, J6,5 = 7.9 Hz, 1H, H-6), 8.04–7.99 (m, 2H, Ar), 7.93–7.87 (m, 
4H, NH2, Ar), 7.65 (d, J = 8.2 Hz, 2H, Ar), 7.33 (d, J = 8.0 Hz, 2H, 
Ar), 5.98 (d, J5,6 = 7.9 Hz, 1H, H-5); 13C NMR (DMSO-d6) δ/ppm: 
165.9 (Cq), 150.9 (Cq), 145.8 (Cq), 139.3 (CH, C-6), 138.5 (Cq), 
135.4 (Cq), 135.2 (Cq), 129.7 (CH, Ar), 129.3 (CH, Ar), 127.0 (CH, 
Ar), 126.8 (CH, Ar), 97.4 (CH, C-5), 20.7 (CH3). (see Supporting 
information Fig. S2) ESI-MS: calcd. for C17H15N3O3S: 341.1; found 
[M+H]+ at m/z 342.1. 
N1-(4'-methoxybiphenyl-4)sulfonylcytosine (5): Synthesis 
was performed according to the general procedure with 4’-
methoxybiphenyl-4-sulfonyl chloride to give the product 5 (283 
mg, 80%) as white crystals. 
M.p. = 227–228 °C; Rf = 0.4; UV (MeOH): λmax/nm: 246; log ε/ 
dm3 mol–1 cm–1: 4.00; IR (KBr) νmax/cm–1: 3366 (m), 3099 (m), 
1670 (s), 16076 (m), 1522 (s), 1487 (s), 1356 (m), 1286 (m), 1250 
(m), 1169 (s), 1140 (w), 1115 (m), 1092 (m), 1024 (w); 1H NMR 
(DMSO-d6) δ/ppm: 8.14 (d, J6,5 = 7.9 Hz, 1H, H-6), 8.02–7.96 (m, 
2H, Ar), 7.93–7.85 (m, 4H, Ar, NH2), 7.75–7.68 (m, 2H, Ar), 7.11–
7.04 (m, 2H, Ar), 5.97 (d, J5,6 = 7.9 Hz, 1H, H-5); 13C NMR (DMSO-
d6) δ/ppm: 165.9 (Cq), 160.0 (Cq), 150.9 (Cq), 145.5 (Cq), 139.4 
(CH, C-6), 134.8 (Cq), 130.3 (Cq), 129.4 (CH, Ar), 128.5 (CH, Ar), 
126.5 (CH, Ar), 114.6 (CH, Ar), 97.4 (CH, C-5), 55.3 (CH3). (see 
Supporting information Fig. S3) ESI-MS: calcd. for C17H15N3O4S: 
357.1; found [M+H]+ at m/z 358.1. 
N1-(4-(dimethylamino)azobenzene-4’-sulfonylcytosine (6): 
Synthesis was performed according to the general procedure 
with 4-(dimethylamino)azobenzene-4’-sulfonyl chloride to give 
the product 6 (212 mg, 57%) as purple crystals.  
M.p. = 263–265 °C; Rf = 0.5; UV (MeOH): λmax/nm: 267 and 454; 
log ε/ dm3 mol–1 cm–1: 4.12 and 4.31; IR (KBr) νmax/cm–1: 3373 
(m), 3115 (m), 2920 (w), 1655 (s), 1605 (s); 1585 (m), 1520 (m), 
1483 (m), 1367 (s), 1358 (s), 1313 (w), 1279 (m), 1234 (w), 1182 
(m), 1140 (s), 1121 (m), 1084 (m), 1020 (w); 1H NMR (DMSO-d6) 
δ/ppm: 8.15 (d, 1H, J6,5 = 7.9 Hz, H-6), 8.09 (d, 2H, J = 8.7 Hz, Ar), 
7.99–7.88 (m, 4H, Ar, NH2), 7.84 (d, 2H, J = 9.1 Hz, Ar), 6.85 (d, 
2H, J = 9.2 Hz, Ar), 5.98 (d, 1H, J5,6 = 7.9 Hz, H-5); 13C NMR 
(DMSO-d6) δ/ppm: 165.9 (Cq), 155.8 (Cq), 153.4 (Cq), 150.9 (Cq), 
142.7 (Cq), 139.3 (CH, C-6), 136.3 (Cq), 130.1 (CH, Ar), 125. 7 (CH, 
Ar), 121.8 (CH, Ar), 111.6 (CH, Ar), 97.5 (CH, C-5), 39.8 (CH3). 
(see Supporting information Fig. S4) ESI-MS: calcd. for 
C18H18N6O3S: 398.1; found [M+H]+ at m/z 399.1. 
5-Morpholinomethyl-N1-sulfonylcytosine derivatives: 
5-Morpholinomethyl-N1-tosylcytosine (8): N1-tosylcytosine (2) 
(200 mg; 0.75 mmol), paraformaldehyde (46 mg, 1.50 mmol, 97%), 
morpholine (131 μL, 1.50 mmol, 99%) and acetic acid (172 μL, 3.00 
mmol) were suspended in absolute ethanol (5 mL). Reaction mixture 
was heated 30 minutes at 100 °C in a microwave reactor. Product 8 
precipitated upon cooling of the mixture and it was purified by 
recrystallization from hot methanol (white crystals, 178 mg, 58%). 
M.p. = 245–246 °C; Rf = 0.6 (CH2Cl2:CH3OH/9:1); UV (MeOH): 
λmax/nm: 247; log ε/dm3 mol–1 cm–1: 3.84; IR (KBr) νmax/cm–1: 3290 
(m), 3098 (m), 3067 (m), 2959 (m), 2922 (m), 2841 (m), 1684 (s), 1517 
(s), 1476 (m), 1451 (m), 1369 (m), 1353 (s), 1340 (m), 1291 (s), 1268 
(w), 1240 (w), 1205 (w), 1188 (w), 1171 (s), 1116 (s), 1088 (s), 1008 
(m); 1H NMR (DMSO-d6) δ/ppm: 8.17 (s, 1H, NH), 8.00 (s, 1H, H-6), 
7.86 (d, J = 8.3 Hz, 2H, Ar), 7.65 (s, 1H, NH), 7.44 (d, J = 8.1 Hz, 2H, 
Ar), 3.63–3.53 (m, 4H, O-CH2), 3.30 (s, 2H, CH2), 2.41 (s, 7H, N-CH2, 
CH3); 13C NMR (DMSO-d6) δ/ppm: 166.2 (Cq), 151.1 (Cq), 145.8 (Cq), 
138.0 (CH, C-6), 134.7 (Cq), 130.0 (CH, Ar), 129.2 (CH, Ar), 104.9 (Cq, 
C-5), 66.6 (O-CH2), 56.3 (CH2), 53.0 (N-CH2), 21.6 (CH3). (see 
Supporting information Fig. S5) HRMS: m/z: calcd for 
C16H21N4O4S+: 365.1284; found 365.1271 [M+H]+. 
5-Morpholinomethyl-N1-(4-morpholino-3-
nitrophenylsulfonyl)cytosine (12): 
a) N1-(4-morpholino-3-nitrophenylsulfonyl)-cytosine (11) (37 
mg; 0.10 mmol), paraformaldehyde (7 mg, 0.23 mmol), morpholine 
(18 μL; 0.20 mmol) and acetic acid (23 μL, 0.40 mmol) were 
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suspended in absolute ethanol (2 mL). Reaction mixture was heated 
30 minutes at 100 °C in a microwave reactor. Product 12 was isolated 
by thin-layer chromatography (eluent: 10% MeOH in CH2Cl2, yellow 
crystals, 23 mg, 48%). 
b) N1-(4-chloro-3-nitrophenylsulfonyl)-cytosine (3) (196 mg, 0.59 
mmol), paraformaldehyde 71 mg, 2.36 mmol), morpholine (206 μL, 
2.36 mmol) and acetic acid (270 μL, 4.72 mmol) were suspended in 
absolute ethanol (5 mL). Reaction mixture was heated 30 minutes at 
100 °C in a microwave reactor. Product 12 was isolated by thin-layer 
chromatography (eluent: 10% MeOH in CH2Cl2, yellow crystals, 155 
mg, 55%). 
M.p. = 272–273 °C; Rf = 0.6 (CH2Cl2:CH3OH/9:1); UV (MeOH): 
λmax/nm: 258 and 404; log ε/dm3 mol–1 cm–1: 4.58 and 3.72; IR (KBr) 
νmax/cm–1: 3420 (s), 3105 (m), 2951 (m), 1692 (s), 1662 (s), 1601 (s), 
1556 (s), 1526 (s), 1478 (m), 1449 (w), 1413 (m), 1379 (m), 1367 (m), 
1352 (m), 1340 (m), 1331 (w), 1296 (m), 1267 (w), 1235 (m), 1178 (s), 
1118 (s), 1007 (m); 1H NMR (DMSO-d6) δ/ppm: 8.37 (d, 1H, J = 2.4 
Hz, Ar), 8.20 (brs, 1H, NH), 8.02 (dd, 1H, J1 = 9.1, J2 = 2.4 Hz, Ar), 7.97 
(s, 1H, H-6), 7.69 (brs, 1H, NH), 7.43 (d, 1H, J = 9.2 Hz, Ar), 3.74–3.50 
(m, 4H, O-CH2), 3.57 (d, 4H, J = 4.0 Hz, O-CH2), 3.30 (s, 2H, CH2), 3.26–
3.19 (m, 4H, N-CH2), 2.39 (m, 4H, N-CH2); 13C NMR (DMSO-d6) δ/ppm: 
165.7 (Cq), 150.7 (Cq), 148.4 (Cq), 137.5 (CH, C-6), 137.5 (Cq), 133.6 
(CH, Ar), 128.8 (CH, Ar), 125.0 (Cq), 120.0 (CH, Ar), 104.4 (Cq, C-5), 
66.1 (O-CH2), 65.6 (O-CH2), 55.8 (CH2), 52.5 (N-CH2), 50.2 (N-CH2). 
(see Supporting information Fig. S6) HRMS: m/z: calcd for 
C19H24N6O7SNa+: 503.1325; found 503.1342 [M+Na]+. 
5-Morpholinomethyl-N1-(4’-methylbiphenyl-
4)sulfonylcytosine (13): N1-(4’-methylbiphenyl-4)-sulfonylcytosine 
(4) (101 mg, 0.30 mmol), paraformaldehyde (19 mg, 0.61 mmol, 
97%), morpholine (52 μL, 0.60 mmol) and acetic acid (68 μL, 1.18 
mmol) were suspended in absolute ethanol (3 mL). Reaction mixture 
was heated 30 minutes at 120 °C in a microwave reactor (stirring 
speed: 600 rpm). Product 13 was isolated by thin-layer 
chromatography (eluent: 10% MeOH in CH2Cl2, white crystals, 69 mg, 
52%). 
M.p. > 300 °C (dec.); Rf = 0.5 (CH2Cl2/CH3OH 9:1); UV (MeOH): 
λmax/nm: 285; log ε/dm3 mol–1 cm–1: 4.69; IR (KBr) ν/cm–1: 3440(s), 
3097 (m), 1691 (s), 1654 (m), 1590 (w), 1518 (w), 1474 (w), 1365 (w), 
1353 (w), 1340 (w), 1298 (w), 1172 (m), 1121 (w), 1089 (w); 1H NMR 
(DMSO-d6) δ/ppm: 8.19 (brs, 1H, NH), 8.02 (d, 3H, J = 8.3 Hz, H-6, Ar), 
7.90 (d, 2H, J = 8.6 Hz, Ar), 7.66 (d, 2H, J = 8.1 Hz, Ar), 7.60 (m, 1H, 
NH), 7.33 (d, 2H, J = 8.0 Hz, Ar), 3.58 (s, 4H, O-CH2), 3.17 (s, 2H, CH2), 
2.46–2.23 (m, 7H, N-CH2, CH3); 13C NMR (DMSO-d6) δ/ppm: 165.7 
(Cq), 150.7 (Cq), 145.8 (Cq), 138.5 (Cq), 137.5 (CH, C-6), 135.4 (Cq), 
135.2 (Cq), 129.7 (CH, Ar), 129.4 (CH, Ar), 127.0 (CH, Ar), 126.8 (CH, 
Ar), 104.5 (Cq, C-5), 66.1 (O-CH2), 55.8 (CH2), 52.5 (N-CH2), 20.7 (CH3). 
(see Supporting information Fig. S7) HRMS: m/z: calcd for 
C22H25N4O4S+: 441.1597; found 441.1595 [M+H]+.  
5-Morpholinomethyl-N1-(4’-methoxylbiphenyl-
4)sulfonylcytosine (14): N1-(4’-methoxylbiphenyl-4)-
sulfonylcytosine (5) (54 mg, 0.15 mmol), paraformaldehyde (10 mg, 
0.32 mmol), morpholine (26 μL, 0.30 mmol) and acetic acid (35 μL, 
0.59 mmol) were suspended in absolute ethanol (3 mL). Reaction 
mixture was heated 30 minutes at 120 °C in a microvawe reactor. 
Product 14 was isolated by thin-layer chromatography (eluent: 10% 
MeOH in CH2Cl2, white crystals, 33 mg, 49%). 
M.p. = 211–212 °C; Rf = 0.6 (CH2Cl2/CH3OH 9:1); UV (MeOH): λmax/nm: 
299; log ε/dm3 mol–1 cm–1: 4.17; IR (KBr) ν/cm–1: 3430(m), 1688 (s), 
1662 (s), 1609 (m), 1592 (m), 1520 (s), 1489 (s), 1397 (w), 1368 (m), 
1354 (m), 1340 (m), 1297 (s), 1270 (m), 1252 (m), 1174 (s), 1116 (m), 
1090 (m); 1H NMR (DMSO-d6) δ/ppm: 8.20 (brs, 1H, NH), 8.07–7.97 
(m, 3H, Ar, H-6), 7.88 (d, 2H, J = 8.7 Hz, Ar), 7.72 (d, 2H, J = 8.8 Hz, 
Ar), 7.67 (brs, 1H, NH), 7.08 (d, 2H, J = 8.8 Hz, Ar), 3.82 (s, 3H, O-CH3), 
3.58 (s, 4H, O-CH2), 3.32 (s, 2H, CH2), 2.41 (s, 4H, N-CH2); 13C NMR 
(DMSO-d6) δ/ppm: 165.7 (Cq), 160.0 (Cq), 150.7 (Cq), 145.5 (Cq), 137.5 
(CH, C-6), 134.8 (Cq), 130.3 (Cq), 129.4 (CH, Ar), 128.5 (CH, Ar), 126.4 
(CH-Ar), 114.6 (CH, Ar), 104.4 (Cq, C-5), 66.1 (O-CH2), 55.8 (CH2), 55.3 
(OCH3), 52.5 (N-CH2). (see Supporting information Fig. S8) HRMS: 
m/z: calcd for C22H25N4O5S+: 457.1546; found 457.1529 [M+H]+. 
5-Morpholinomethyl-N1-(4-(dimethylamino)azobenzene-4’-
sulfonylcytosine (15): N1-(4-(dimethylamino)azobenzene-4’-
sulfonylcytosine (6) (60 mg, 0.15 mmol), paraformaldehyde (11 mg, 
0.35 mmol), morpholine (26 μL, 0.30 mmol) and acetic acid (34 μL, 
0.59 mmol) were suspended in absolute ethanol (5 mL). Reaction 
mixture was heated 60 minutes at 120 °C in a microwave reactor 
(stirring speed: 600 rpm). Product 15 was isolated by thin-layer 
chromatography (eluent: 10% MeOH in CH2Cl2, red crystals, 23 mg, 
30%). 
M.p. > 300 °C (dec.); Rf = 0.6 (CH2Cl2/CH3OH 9:1); UV (MeOH): 
λmax/nm: 272 and 455; log ε/dm3 mol–1 cm–1: 4.03 and 4.26; IR (KBr) 
ν/cm–1: 3447 (s), 1607 (m), 1520 (w), 1367 (m), 1178 (m), 1142 (m), 
1117 (m), 1084 (m); 1H NMR (DMSO-d6) δ/ppm: 8.22 (brs, 1H, NH), 
8.09 (d, 2H, J = 8.7 Hz, Ar), 8.04 (s, 1H, H-6), 7.91 (d, 2H, J = 8.7 Hz, 
Ar), 7.84 (d, 2H, J = 9.2 Hz, Ar), 7.70 (brs, 1H, NH), 6.87 (d, 2H J = 9.2 
Hz, Ar), 3.58 (s, 4H, O-CH2), 3.32 (s, 2H, CH2+H2O), 3.10 (s, 6H, CH3), 
2.41 (s, 4H, N-CH2); 13C NMR (DMSO-d6) δ/ppm: 165.7 (Cq), 155.8 
(Cq), 153.4 (Cq), 142.7 (Cq), 137.4 (CH, C-6), 136.3 (Cq), 130.2 (CH-Ar), 
125.7 (CH-Ar), 121.8 (CH-Ar), 111.6 (CH-Ar), 104.6 (Cq, C-5), 66.1 (O-
CH2), 55.7 (CH2), 52.5 (N-CH2). (see Supporting information Fig. S9) 
HRMS: m/z: calcd for C23H28N7O4S+: 498.1923; found 498.1908 
[M+H]+.  
Byproducts: 
1-Imino-3-morpholinoallyl-3-tosylurea (9) 
Rf = 0.4 (CH2Cl2/CH3OH 9:1); 1H NMR (DMSO-d6) δ/ppm: 9.90 (bs, 1H, 
NH), 9.74 (bs, 1H, NH), 8.69 (s, 1H, NH), 7.88 (d, J = 13.4 Hz, 1H, CH), 
7.65 (d, J = 8.1 Hz, 2H, Ar), 7.22 (d, J = 8.0 Hz, 2H, Ar), 4.75 (d, J = 13.4 
Hz, 1H, CH), 3.75–3.54 (m, 4H, O-CH2), 3.30–3.18 (m, 4H, N-CH2), 2.33 
(s, 3H, CH3).; 13C NMR (DMSO-d6) δ/ppm: 162.6 (Cq), 157.0 (Cq), 151.5 
(CH), 142.3 (Cq), 139.8 (Cq), 128.1 (CH-Ar), 126.6 (CH-Ar), 80.6 (CH), 
65.4 (CH2), 20.6 (CH3). (see Supporting information Fig. S10) ESI-
MS: calcd. for C15H20N4O4S: 352.1; found [M+H]+ at m/z 353.0 
and 351.0 at m/z [M-H]-. 
4-Tosylmorpholine (10)  
Rf = 0.9 (CH2Cl2/CH3OH 9:1); 1H NMR (DMSO-d6) δ/ppm: 7.68–7.58 
(m, 2H, Ar), 7.53–7.43 (m, 2H, Ar), 3.72–3.54 (m, 4H, O-CH2), 2.91–
2.78 (m, 4H, N-CH2), 2.42 (s, 3H, CH3); 13C NMR (DMSO-d6) δ/ppm: 
143.8 (Cq), 131.5 (Cq), 129.8 (CH-Ar), 127.6 (CH-Ar), 65.2 (O-CH2), 45.8 
(N-CH2), 21.0 (CH3). (see Supporting information Fig. S11) ESI-MS: 
calcd. for C11H15NO3S: 241.1; found [M+H]+ at m/z 241.9. 
N1-(4-Morpholino-3-nitrophenylsulfonyl)cytosine (11): 
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Rf = 0.3 (CH2Cl2/CH3OH 9:1); 1H NMR (DMSO-d6) δ/ppm: 8.36 (d, J = 
2.4 Hz, 1H, Ar), 8.07 (d, J6,5 = 7.9, 1H, H6), 8.01 (dd, J1 = 9.1, J2 = 2.4 
Hz, 1H, Ar), 7.93 (s, 2H, NH2), 7.43 (d, J = 9.2 Hz, 1H, Ar), 5.94 (d, J5,6 
= 7.9 Hz, 1H, H5), 3.74–3.66 (m, 4H, O-CH2), 3.27–3.19 (m, 4H, N-CH2); 
13C NMR (DMSO-d6) δ/ppm: 166.0 (Cq), 151.0 (Cq), 148.4 (Cq), 139.4 
(CH), 137.3 (Cq), 133.6 (CH-C6), 128.8 (CH), 125.0 (Cq), 120.0 (CH), 
97.3 (CH-C5), 65.6 (O-CH2), 50.2 (N-CH2). (see Supporting 
information Fig. S12) ESI-MS: calcd. for C14H15N5O6S: 381.1; 
found [M+H]+ at m/z 382.0. 
Crystalographic data 
Crystal data, data collection and refinement parameters are 
summarized in Table 5. Data collection was performed at room 
temperature on an Oxford Diffraction Xcalibur Nova R diffractometer 
with the microfocusing Cu tube (λ = 1.54179 Å). Data reduction and 
cell refinement were carried out using the CRYSALIS PRO software.27 
Structure was solved by direct methods with SIR201428 and refined 
by a full matrix least-squares refinement based on F2, with SHELXL29. 
Molecular illustrations were prepared with ORTEP-330 and 
MERCURY31 included in the WinGX package32. Calculations of 
molecular geometries and crystal packing parameters were 
performed with PLATON33. Hydrogen atoms were located in the 
Fourier map and refined freely. CCDC 1588667 contains the 
supplementary crystallographic data. These data can be obtained 
free of charge via http://www.ccdc.cam.ac.uk/conts/retrieving.html, 
or from the Cambridge Crystallographic Data Centre, 12 Union Road, 
Cambridge CB2 1EZ, UK; fax: (+44) 1223-336-033; or e-mail: 
deposit@ccdc.cam.ac.uk. 
Table 5. Crystallographic data 
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Brutto formula C15H24N4O6S 
Formula weight (gmol-1) 388.44 
Crystal color and habit colourless plate 
Crystal dimensions (mm) 0.04 x 0.06 x 0.2 
Space group P-1 
a (Å) 6.5612 (3) 
b (Å) 9.2289 (4) 
c (Å) 15.5715 (7) 
α (°) 95.807 (4) 
β (°) 94.598 (4) 
γ (°) 98.710 (4) 
V (Å3) 922.86 (7) 
Ζ 2 
μ (CuKα) (mm-1) 1.918 
Absorption correction multi-scan 
F(000) 414 
 max () 75.881 
No. refl. measured 7824 
No. refl. unique 3769 
No. refl. observed [I>2σ(I)] 3369 
Rint 0.0309 
Rσ 0.0489 
Parameters 280 
R1 [I>2σ(I)] 0.0537 
wR2, all 0.1531 
S 1.001 
ρmax, ρmin (eÅ-3) 0.65; -0.32 
Cell culturing 
Human tumor cell lines U251 (glioblastoma) and MCF-7 (breast 
carcinoma) cells were cultured as monolayers, while MOLT-4 (acute 
lymphoblastic leukemia) cell line was maintained in Dulbecco's 
modified Eagle medium (DMEM), supplemented with 10% fetal 
bovine serum (FBS), 2mM L-glutamine, 100 U/ml penicillin and 100 
μg/ml streptomycin in a humidified atmosphere with 5% CO2 at 37˚C. 
Proliferation assays 
The cells were inoculated onto a series of standard 96-well 
microtiter plates on day 0, at 1×104 to 3×104 cells/ml, depending on 
the doubling times of specific cell line. Test agents were then added 
in five 10-fold dilutions (10-8 to 10-4 M) and incubated for a further 
72 hours. Working dilutions were freshly prepared on the day of 
testing. After 72 hours of incubation the cell growth rate was 
evaluated by performing the MTT assay, as described previously.11,34 
Each test point was performed in quadruplicate in at least two 
individual experiments. The results were expressed as IC50, a 
concentration necessary for 50% of inhibition. Each result is a mean 
value from at least two separate experiments. 
Conclusions 
Fast and efficient synthetic method for the synthesis of 5-
morpholinomethyl-N1-sulfonylcytosine derivatives has been 
established. N1-sulfonylcytosine derivatives 3–6 were prepared 
by the condensation of pyrimidine bases with different sulfonyl 
chlorides, and then transformed to C5-substituted N1-
sulfonylcytosines (8, 12-15) in moderate to very good yield (up 
to 65%). Microwave assisted reaction significantly shortened 
the reaction time and favored formation of Mannich product 
over numerous possible byproducts. Shortened reaction time 
adequately addressed the problem of N-SO2 bond instability. 
Moreover, it has been found that temperature controls the 
reaction pathway. As a result of the cytosine ring opening, 
interesting tosylurea derivative 9 has been isolated from the 
reaction at lower temperature (80 C). At higher temperatures 
(100 C and 120 C), 9 undergoes acid catalyzed cyclization to 
form starting TsC and participates in the Mannich reaction. In 
this sense, elevated temperatures promote formation of the 
Mannich product. Presented method constitutes a robust tool 
for introduction of new pharmacophores, such as cyclic amine 
morpholine, into biologically active pyrimidines. Two of the 
newly synthesized compounds, 13 and 14, showed a very strong 
(micromolar) antiproliferative activity on U251, MCF7 and 
MOLT-4 tumor cell lines. In addition, scope of this method could 
be expanded to various amine, as well as pyrimidine derivatives, 
and this issue will be studied furtherly. 
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